- Home
- GNFT vs CHRS Comparison
GNFT vs CHRS Comparison
Compare GNFT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- CHRS
- Stock Information
- Founded
- GNFT 1999
- CHRS 2010
- Country
- GNFT France
- CHRS United States
- Employees
- GNFT 167
- CHRS N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNFT Health Care
- CHRS Health Care
- Exchange
- GNFT Nasdaq
- CHRS Nasdaq
- Market Cap
- GNFT 172.2M
- CHRS 191.3M
- IPO Year
- GNFT 2019
- CHRS 2014
- Fundamental
- Price
- GNFT $3.50
- CHRS $1.49
- Analyst Decision
- GNFT Strong Buy
- CHRS Strong Buy
- Analyst Count
- GNFT 1
- CHRS 4
- Target Price
- GNFT $13.00
- CHRS $5.38
- AVG Volume (30 Days)
- GNFT 6.7K
- CHRS 2.2M
- Earning Date
- GNFT 09-19-2024
- CHRS 11-06-2024
- Dividend Yield
- GNFT N/A
- CHRS N/A
- EPS Growth
- GNFT N/A
- CHRS N/A
- EPS
- GNFT 0.47
- CHRS N/A
- Revenue
- GNFT $86,225,222.00
- CHRS $304,340,000.00
- Revenue This Year
- GNFT $145.20
- CHRS $2.47
- Revenue Next Year
- GNFT N/A
- CHRS N/A
- P/E Ratio
- GNFT $7.10
- CHRS N/A
- Revenue Growth
- GNFT 175.45
- CHRS 44.19
- 52 Week Low
- GNFT $3.31
- CHRS $0.66
- 52 Week High
- GNFT $6.42
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- GNFT 37.48
- CHRS 51.20
- Support Level
- GNFT $3.44
- CHRS $1.44
- Resistance Level
- GNFT $3.90
- CHRS $1.60
- Average True Range (ATR)
- GNFT 0.12
- CHRS 0.13
- MACD
- GNFT 0.01
- CHRS -0.02
- Stochastic Oscillator
- GNFT 26.00
- CHRS 30.95
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.